πŸ”¬Deep Research

IRWD β€” Ironwood Pharmaceuticals Β· catalysts, narrative & risks

Β·21 sourcesIRWD forecast β†’

Overview / Current Snapshot (as of 2026-10-03)

Ironwood Pharmaceuticals (Nasdaq: IRWD) is a Boston-based, GI-focused biopharmaceutical company whose commercial business is anchored by LINZESS (linaclotide), marketed in the U.S. through an AbbVie collaboration and internationally under CONSTELLA via AstraZeneca/partners [14], [18]. The stock closed at ~$3.64 on October 2, 2026 (down ~3.2% that day), with a market cap of ~$601.5M, a 52-week range of $1.41–$5.78, a P/E of ~4.6–4.7, and low beta (~0.21) [14], [18], [21]. The shares have clearly come off their recent highs after a sharp mid-2026 rally.

Key Recent Catalysts (July–October 2026)


AI-assisted research from the K3vl4r desk β€” not personalized investment advice. More research β†’